Patrick Melvin Joins Oncology Leadership Team at INC Research
News Feb 17, 2011
INC Research, LLC., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, welcomes Patrick Melvin as executive director, Oncology who will be leveraging his extensive hematology/oncology trial experience for Phase I first-in-man studies through pivotal global Phase IV programs.
"Our reputation as leaders in supporting complex oncology clinical trials enables us to attract proven leadership talent experts like Patrick to join our team and support continued growth and excellence as an oncology CRO," said Nick Kenny, PhD, executive vice president, Oncology at INC Research.
"His experience will be a great asset to help us keep pace with advancements in hematology and oncology clinical trial design, particularly as early phase research is playing a more significant role to better help reduce risk in later phases, and to provide thoughtful support to our clients", said Kenny.
Melvin has nearly 20 years experience in clinical drug development in the fields of hematology and oncology. Previously at PPD and Premier Research, Melvin held increasing responsibilities for the operations, strategic planning and corporate development of a growing portfolio of oncology business.
His key early phase experience includes multiple variations of early-phase hematology/oncology trial designs including traditional dose-escalating maximum tolerated dose design as well as various optimal dose designs for targeted agents. Melvin's later phase hematology/oncology experience includes extensive pivotal trial experience in the United States, Western and Eastern Europe, Latin America, and Asia-Pacific. He holds a BSc from the University of North Carolina, Wilmington.
INC Research has conducted more than 350 Phase I through IV oncology trials with nearly 35,000 patients and 4,000 investigative sites around the globe. The team has investigated nearly 130 new and various anticancer therapies, including the introduction of more than 30 new chemical entities (NCEs) in first-in-man trials. The Oncology practice is dedicated to advancing scientific knowledge and helping patients through focused, thoughtful management of critical oncology trials.
INC Research is proud to co-sponsor events such as the upcoming International Symposium on Targeted Anticancer Therapies, organized by the NDDO Education Foundation in partnership with the European Society for Medical Oncology (ESMO) and the US National Cancer Institute (NCI) on March 7-9 in Paris.